Related Concept Videos
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
Dose-Response Relationship: Potency and Efficacy
Volume of Distribution
Receiver Operating Characteristic Plot
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.
POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer.
National Trends in Early-Onset Colorectal Cancer: Incidence and Challenges in the Republic of Ireland.
Related Experiment Video
Updated: Jul 27, 2025

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
Clinical Utility of
Darren Cowzer1, Fergus Keane1, Geoffrey Y Ku1,2
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Positron emission tomography-computed tomography (PET-CT) is crucial for managing esophageal and gastroesophageal junction adenocarcinoma. This review highlights its role in staging, prognostication, and guiding therapy for improved patient outcomes.
More Related Videos
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
07:13Applications of In Vivo Functional Testing of the Rat Tibialis Anterior for Evaluating Tissue Engineered Skeletal Muscle Repair
Published on: October 7, 2016
Area of Science:
- Oncology
- Nuclear Medicine
- Gastroenterology
Background:
- Esophageal adenocarcinoma and gastroesophageal junction adenocarcinoma are uncommon but have a rising incidence in young adults.
- These cancers traditionally have a poor prognosis, with most patients developing metastatic disease despite multimodality treatment.
- Long-term outcomes for esophageal and GEJ adenocarcinoma remain suboptimal.
Purpose of the Study:
- To review the key data on the use of PET-CT in managing locally advanced esophageal and GEJ adenocarcinoma.
- To focus on the applications of PET-CT in staging, prognostication, and therapy adaptation.
- To discuss the role of PET-CT in neoadjuvant treatment and surveillance strategies.
Main Methods:
- Review of prospective and retrospective studies evaluating PET-CT in esophageal and GEJ adenocarcinoma.
- Analysis of data concerning PET-CT's accuracy in staging and prognostication.
- Evaluation of studies on PET-CT adapted neoadjuvant therapy and surveillance protocols.
Main Results:
- PET-CT has emerged as a key tool in the management of esophageal and GEJ adenocarcinoma over the last decade.
- Evidence supports its utility in improving staging accuracy and patient prognostication.
- PET-CT guided therapy adaptation in the neoadjuvant setting and surveillance shows promise.
Conclusions:
- PET-CT plays a significant role in the multidisciplinary management of locally advanced esophageal and GEJ adenocarcinoma.
- Its application in staging, prognostication, and guiding therapy can potentially optimize patient management and outcomes.
- Further integration of PET-CT in treatment protocols and surveillance is warranted.